Every rheumatologist knows this patient. Her ASDAS is 3.4. Her CRP is normal, her MRI is quiet, and she is on her third biologic. The reflex is to reach for a fourth. Abstracts from ACR Convergence 2026 make a quietly radical case against this reflex.
All News
Among the groundbreaking clinical trials and new treatment strategies, one of the most important stories may be about something we aren't doing enough of: addressing obesity and cardiometabolic risk in our patients with psoriatic arthritis (PsA).
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
For someone who has spent so much of his career recognizing the work of others, it is fitting that Dr. John J. “Jack” Cush should have his own moment in the spotlight.
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern https://t.co/cTVvyXBbug
